Circulating DNA in the neoadjuvant setting of early stage colon cancer

References

• Argilés G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291–1305.
   PubMed Web of Science ®Google Scholar
• André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III Colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–3116.
   PubMed Web of Science ®Google Scholar
• Shah MA, Renfro LA, Allegra CJ, et al. Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: analysis from modern-era adjuvant studies in the adjuvant colon cancer end points (ACCENT) database. J Clin Oncol. 2016;34(8):843–853.
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219–3226.
   PubMed Web of Science ®Google Scholar
• Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II Colon cancer. Sci Transl Med. 2016;8:346ra92.
   PubMed Web of Science ®Google Scholar
• Tie J, Cohen JD, Wang Y, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III Colon cancer. JAMA Oncol. 2019;5(12):1710–1717.
   PubMed Web of Science ®Google Scholar
• Tie J, Cohen JD, Lo SN, et al. Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: individual patient pooled analysis of three cohort studies. Int J Cancer. 2021;148(4):1014–1026.
   PubMed Web of Science ®Google Scholar
• Verbus EA, Rossi AJ, Luna AJ, et al. Circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy for patients with stage 2A colon cancer (COBRA). Ann Surg Oncol. 2021;28(8):4095–4097.
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Nakamura Y, Kotani D, et al. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci. 2021;112(7):2915–2920.
   PubMed Web of Science ®Google Scholar
• Circulating tumour DNA analysis informing adjuvant chemotherapy in stage III colon cancer: a multicentre phase II/III randomised controlled study (DYNAMIC-III). Available at: https://www.australianclinicaltrials.gov.au/anzctr/trial/ACTRN12617001566325. (accessed on 27.01.2022).
   Google Scholar
• A study to evaluate the use of circulating tumour DNA to guide adjuvant chemotherapy on recurrence-free survival in patients with stage II colon or rectal cancer. Available at: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12615000381583. (accessed on 27.01.2022).
   Google Scholar
• Hendlisz A, Golfinopoulos V, Deleporte A, et al. Preoperative chemosensitivity testing as predictor of treatment benefit in adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (belgian group for digestive oncology) multicentric study. BMC Cancer. 2015;15:173.
   PubMed Web of Science ®Google Scholar
• Garrigou S, Perkins G, Garlan F, et al. A study of hypermethylated circulating tumor DNA as a universal colorectal cancer biomarker. Clin Chem. 2016;62(8):1129–1139.
   PubMed Web of Science ®Google Scholar
• Ryan R, Gibbons D, Hyland JM, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005;47(2):141–146.
   PubMed Web of Science ®Google Scholar
• Seymour MT, Morton D. FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for Colon cancer. J Clin Oncol. 2019;37(15_suppl):3504–3504.
   Web of Science ®Google Scholar
• Tie J, Cohen JD, Wang Y, et al. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut. 2019;68(4):663–671.
   PubMed Web of Science ®Google Scholar
• Khakoo S, Carter PD, Brown G, et al. MRI tumor regression grade and circulating tumor DNA as complementary tools to assess response and guide therapy adaptation in rectal cancer. Clin Cancer Res. 2020;26(1):183–192.
   PubMed Web of Science ®Google Scholar
• Sclafani F, Chau I, Cunningham D, et al. KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. Sci Rep. 2018;8(1):1445.
   PubMed Web of Science ®Google Scholar
• Tie J, Wang Y, Cohen J, et al. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: a prospective cohort study. PLoS Med. 2021;18(5):e1003620.
   PubMed Web of Science ®Google Scholar
• Loupakis F, Sharma S, Derouazi M, et al. Detection of molecular residual disease using personalized circulating tumor DNA assay in patients with colorectal cancer undergoing resection of metastases. J Clin Oncol Precis Oncol. 2021;5:PO.21.00101.
   PubMed Web of Science ®Google Scholar
• Siravegna G, Mussolin B, Buscarino M, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21(7):795–801.
   PubMed Web of Science ®Google Scholar
• Garlan F, Laurent-Puig P, Sefrioui D, et al. Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study). Clin Cancer Res. 2017;23(18):5416–5425.
   PubMed Web of Science ®Google Scholar
• Spindler KG, Boysen AK, Palisgaard N, et al. A systematic review and Meta-analysis of the prognostic value of total cell-free DNA quantification in metastatic colorectal cancer. Ann Oncol. 2016;27(Supplement 6):vi149–vi206.
   Google Scholar
• Hamfjord J, Guren TK, Dajani O, et al. Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy. Ann Oncol. 2019;30(7):1088–1095.
   PubMed Web of Science ®Google Scholar
• Mouliere F, Thierry AR. The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients. Expert Opin Biol Ther. 2012;12(sup1):S209–S215.
   PubMed Web of Science ®Google Scholar
• Norton SE, Lechner JM, Williams T, et al. A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. Clin Biochem. 2013;46(15):1561–1565.
   PubMed Web of Science ®Google Scholar
• Alcaide M, Cheung M, Hillman J, et al. Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR. Sci Rep. 2020;10(1):12564.
   PubMed Web of Science ®Google Scholar
• Thomsen CB, Andersen RF, Lindebjerg J, et al. Correlation between tumor-specific mutated and methylated DNA in colorectal cancer. J Clin Oncol Precis Oncol. 2019;3:1–8.
   PubMed Web of Science ®Google Scholar